Key takeaways
Healthcare providers generally do not recommend starting Zepbound at 5 mg.
The recommended 2.5 mg starting dose is intentionally lower to help the body adjust to the medication and reduce the likelihood of side effects.
Zepbound 5 mg is an effective maintenance dose for weight loss.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Healthcare providers generally do not recommend starting Zepbound at 5 mg.
The recommended 2.5 mg starting dose is intentionally lower to help the body adjust to the medication and reduce the likelihood of side effects.
Zepbound 5 mg is an effective maintenance dose for weight loss.
Can you start Zepbound (tirzepatide) at 5 mg instead of the standard 2.5 mg dose? In most cases, the answer is no. Zepbound 2.5 mg is the starting dose for a reason, and 5 mg is a maintenance dose. It's natural to be eager for results from a weight loss medication, but the lower starting dose helps the body adjust.
Can I start Zepbound at 5 mg?
No, it's generally not recommended to start Zepbound at 5 mg. The recommended starting dose is 2.5 mg, which is meant for treatment initiation and is not approved as a maintenance dose. Based on findings from clinical trials, the manufacturer advises healthcare providers to increase to 5 mg only after four weeks on 2.5 mg. After at least four weeks on 5 mg, they may increase to 7.5 mg.
This gradual dose escalation process is called titration. Based on the standard titration schedule, which includes at least four weeks at each dose, it takes about five months of treatment to reach the maximum Zepbound dose of 15 mg (in week 21).
The schedule is intended to reduce gastrointestinal side effects, such as nausea and vomiting, as the dose increases. In practice, healthcare providers may increase the dose more slowly. According to one analysis of about 15,000 patient records of people with type 2 diabetes taking tirzepatide, the average time to a first dose increase was 59 days — about twice as long as the standard four-week timeline.
While Zepbound's recommended starting dose is 2.5 mg, healthcare providers may sometimes consider starting at 5 mg for people switching to Zepbound from another GLP-1 medication.
In one study, adults with type 2 diabetes who were already taking a GLP-1 medication switched directly to tirzepatide 5 mg and generally tolerated the change. However, the study did not specifically examine people taking Zepbound for weight loss or those switching from Wegovy (semaglutide) 2.4 mg.
Even in these scenarios, however, healthcare providers may still recommend starting Zepbound at 2.5 mg to reduce the intensity of side effects.
Why is the Zepbound starting dose 2.5 mg?
The Zepbound 2.5 mg starting dose is meant to help reduce the risk of stomach-related side effects as the body adjusts. Starting at a lower dose — and increasing to 5 mg after four weeks — can help people stay on treatment, rather than stopping due to intolerable stomach pain, nausea, or other side effects.
Starting Zepbound at 5 mg instead of 2.5 mg doubles the recommended starting dose, which may lead to more intense side effects, especially for people taking a GLP-1 for the first time. In one study of people who stopped taking a GLP-1 such as Zepbound or Wegovy (see how they compare) within the first year, about 15% said they stopped because they couldn't tolerate the side effects..
Starting at 2.5 mg vs. 5 mg and following the recommended dose escalation schedule may help reduce side effects that could otherwise make treatment difficult to continue.
How effective is 5 mg of Zepbound?
Zepbound can produce meaningful weight loss results at the 5 mg dose. In a clinical trial of people with obesity or overweight, those taking Zepbound 5 mg lost 15% of their body weight on average in 72 weeks (less than a year and a half). Like other participants, they began treatment at 2.5 mg before increasing their dose. They also had improvements in blood pressure and cholesterol levels.
Side effects of Zepbound 5 mg
Even though Zepbound’s gradual dose escalation schedule is designed to lessen side effects, side effects still occur at Zepbound 5 mg. Here’s what people reported in clinical trials:
Side effect of Zepbound 5 mg | Percentage reported in clinical trials |
Nausea | 25% |
Diarrhea | 19% |
Constipation | 17% |
Vomiting | 8% |
Abdominal pain | 9% |
Indigestion/upset stomach | 9% |
Injection site reactions | 6% |
Fatigue | 5% |
Allergic reactions to Zepbound | 5% |
Hair loss | 5% |
Zepbound's side effects tend to be most intense when starting Zepbound or increasing the dose. Talk to a healthcare provider, such as on Ro, about any side effects that concern you during dose escalation.
If side effects feel unmanageable at the 5 mg dose, talk to your healthcare provider. They may recommend delaying further dose increases, returning to the next lowest dose, or temporarily stopping the medication.
Zepbound dosing basics
According to its prescribing information, there are six dosage strengths of Zepbound:
2.5 mg
5 mg
7.5 mg
10 mg
12.5 mg
15 mg
Of these dosage strengths, the maintenance doses for weight loss are 5 mg, 10 mg, and 15 mg weekly. (For obstructive sleep apnea, the maintenance doses are 10 mg and 15 mg.) A maintenance dose is the dose used to support weight management over time
In general, healthcare providers start Zepbound at 2.5 mg once weekly for four weeks, followed by 5 mg. If needed, healthcare providers may then increase the dose by 2.5 mg after at least four weeks on the current dose. Based on response to the medication and tolerance for side effects, a healthcare provider may increase the dose more slowly than that — but it's not recommended to increase it more quickly.
Here’s what a typical Zepbound dose escalation schedule might look like:
Timeline | Weekly Zepbound dose if increasing every 4 weeks |
Weeks 1–4 | 2.5 mg |
Weeks 5–8 | 5 mg |
Weeks 9–12 | 7.5 mg |
Weeks 13–16 | 10 mg |
Weeks 17–20 | 12.5 mg |
Weeks 21+ | 15 mg |
*This is an example of the fastest dose escalation schedule, not a schedule everyone needs to follow. Your healthcare provider may keep you on a dose longer or stop increasing it once you reach an effective maintenance dose.
Do you lose more weight on higher doses of Zepbound?
Yes, people generally lose more weight on higher doses of Zepbound. For example, in a 72-week study of over 2,500 adults with obesity or overweight, people who took 15 mg of Zepbound lost an average of 21% of their body weight. Those who took 10 mg lost 19.5%, while those who took 5 mg lost 15%.
Higher doses of Zepbound also came with slightly higher discontinuation rates. About 6% of people taking 15 mg stopped treatment due to side effects, compared with about 4% of those taking 5 mg.
So, just because more weight loss is possible on Zepbound 15 mg does not necessarily mean it's the best dose for every person. The prescribing information advises weighing treatment response and tolerability when choosing a maintenance dose, and for some people that dose may be 5 mg.
Bottom line
Zepbound 5 mg is a maintenance dose, not a starting dose. Here's why healthcare providers generally do not start Zepbound at 5 mg:
The recommended starting dose is 2.5 mg, which is intentionally lower to help the body adjust and reduce the intensity of side effects.
For some people already taking another GLP-1 medication, a healthcare provider may consider starting tirzepatide at 5 mg.
Zepbound 5 mg is an effective maintenance dose for weight loss and other health markers, such as blood pressure and cholesterol. Higher doses produced more weight loss on average, but the best dose balances results with manageable side effects.
The most common side effects of Zepbound 5 mg include nausea, diarrhea, constipation, abdominal pain, and vomiting.
Zepbound dosing usually follows a gradual escalation schedule, with at least four weeks between dose increases. Not everyone needs to reach the highest dose.
Frequently asked questions (FAQs)
Is it safe to start Zepbound at 5 mg?
Healthcare providers generally do not recommend starting at 5 mg because the starting dose of Zepbound is 2.5 mg. Starting at 5 mg doubles the recommended starting dose and may increase the likelihood of side effects such as nausea, diarrhea, and constipation. For some people, side effects are intense enough that they stop taking Zepbound — an outcome a lower starting dose may help prevent.
Is 5 mg of Zepbound too much?
Zepbound 5 mg is the lowest maintenance dose of Zepbound for weight management. Some people stay at 5 mg without escalating to a higher dose. If side effects feel too intense at 5 mg, contact your healthcare provider. They will decide whether you should stay at your current dose, change your treatment plan, or temporarily stop treatment.
What happens if you start tirzepatide at 5 mg?
Starting tirzepatide at 5 mg may cause more intense side effects, since you’re beginning at twice the usual starting dose. The recommended 2.5 mg starting dose is meant to reduce the risk of stomach-related side effects as the body adjusts, which may help people stay on treatment.
How long does it take Zepbound 5 mg to kick in?
Zepbound typically reaches its maximum concentration in the bloodstream within about 24 hours of a dose. But it takes roughly four weeks of weekly dosing at the same dose to reach a steady level in the body. Visible weight loss takes longer, happens gradually, and the timing and amount of weight loss vary from person to person. In clinical trials, participants lost roughly 3%–4% of their starting body weight during the first four weeks and around 6% by week eight, on average. All participants began treatment at 2.5 mg before increasing their dose.
Can you take two 2.5 mg Zepbound doses to make 5 mg?
Two 2.5 mg doses contain a total of 5 mg of tirzepatide. However, you should not combine doses or change how you take Zepbound unless your healthcare provider specifically instructs you to do so. Zepbound is available in a 5 mg strength, and it's important to follow your prescribed dose and administration instructions.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
References
Almandoz, J. P., Lingvay, I., Morales, J., et al. (2020). Switching between glucagon-like peptide-1 receptor agonists: Rationale and practical guidance. Clinical Diabetes, 38(4), 390–402. doi: 10.2337/cd19-0100. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7566932/
Gasoyan, H., Butsch, W. S., Casacchia, N. J., et al. (2025). Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity, 33(12), 2296–2303. doi: 10.1002/oby.70058. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12636059/
Jabbour, S., Paik, J. S., Aleppo, G., et al. (2024). Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: Clinical expectations in the first 12 weeks of treatment. Endocrine Practice, 30(8), 701–709. doi: 10.1016/j.eprac.2024.05.005. Retrieved from https://www.endocrinepractice.org/article/S1530-891X(24)00515-9/fulltext
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. doi: 10.1056/nejmoa2206038. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2206038
Mody, R., Desai, K., Teng, C., et al. (2025). Characteristics and dosing patterns of tirzepatide users with type 2 diabetes in the United States. Diabetes Therapy, 16(2), 307–327. doi: 10.1007/s13300-024-01684-6. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11794899/
Rubino, D. M., Pedersen, S. D., Connery, L., et al. (2025). Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism, 27(4), 1826–1835. https://doi.org/10.1111/dom.16176. Retrieved from https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.16176
Schneck, K. & Urva, S. (2024). Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics & Systems Pharmacology, 13(3), 494–503. doi: 10.1002/psp4.13099. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10962491/
U.S. Food and Drug Administration (FDA). (2026). Highlights of prescribing information: Zepbound (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf














